{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T08:04:29Z","timestamp":1779782669443,"version":"3.53.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"am","delay-in-days":319,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["K24 AG078179"],"award-info":[{"award-number":["K24 AG078179"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01 AG068192"],"award-info":[{"award-number":["R01 AG068192"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U54 H6007963"],"award-info":[{"award-number":["U54 H6007963"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["P30 AR072577"],"award-info":[{"award-number":["P30 AR072577"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["R21 AR078839"],"award-info":[{"award-number":["R21 AR078839"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017704","name":"Fundaci\u00f3n Bechara","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006260","name":"Rheumatology Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006260","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.cct.2025.108000","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T19:27:28Z","timestamp":1752607648000},"page":"108000","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Rationale and design of the rheumatoid arthritis non-responders to treatment (RANT) study: Use of a bioinformatics platform and \u201cdecentralized\u201d clinical recruitment design"],"prefix":"10.1016","volume":"156","author":[{"given":"Gregory C.","family":"McDermott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Jeffway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thany","family":"Seyok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harrison","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Myasoedova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"John M.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Giles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Coblyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Helfgott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Massarotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Sands","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Weinblatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Schmajuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaleb","family":"Michaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassandra","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Churchill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine P.","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cct.2025.108000_bb0005","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1056\/NEJMra2103726","article-title":"Rheumatoid arthritis \u2014 common origins, divergent mechanisms","volume":"388","author":"Gravallese","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cct.2025.108000_bb0010","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/acr.24596","article-title":"2021 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthrit. Care Res. (Hoboken)"},{"key":"10.1016\/j.cct.2025.108000_bb0015","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/annrheumdis-2021-220973","article-title":"EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis","volume":"81","author":"Nagy","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cct.2025.108000_bb0020","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1136\/annrheumdis-2017-212862","article-title":"Defining refractory rheumatoid arthritis","volume":"77","author":"Buch","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cct.2025.108000_bb0025","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41584-020-00541-7","article-title":"Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis","volume":"17","author":"Buch","year":"2021","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.cct.2025.108000_bb0030","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.jacbts.2021.01.011","article-title":"Decentralized clinical trials: the future of medical product development?","volume":"6","author":"Van Norman","year":"2021","journal-title":"JACC Basic Transl. Sci."},{"key":"10.1016\/j.cct.2025.108000_bb0035","series-title":"The Evolving Role of Decentralized Clinical Trials and Digital Health Technologies","author":"U.S. Food and Drug Administration","year":"2023"},{"key":"10.1016\/j.cct.2025.108000_bb0040","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/cpt.1441","article-title":"Decentralized trials in the age of real-world evidence and inclusivity in clinical investigations","volume":"106","author":"Khozin","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.cct.2025.108000_bb0045","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/acr2.11256","article-title":"Testing the effects of disease-modifying antirheumatic drugs on vascular inflammation in rheumatoid arthritis: rationale and design of the TARGET trial","volume":"3","author":"Giles","year":"2021","journal-title":"ACR Open Rheumatol."},{"key":"10.1016\/j.cct.2025.108000_bb0050","first-page":"11","article-title":"Relationship between risk of atherosclerotic cardiovascular disease, inflammation, and coronary microvascular dysfunction in rheumatoid arthritis","author":"Weber","year":"2022","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.cct.2025.108000_bb0055","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1136\/ard-2022-223302","article-title":"Reducing cardiovascular risk with immunomodulators: a randomised active comparator trial among patients with rheumatoid arthritis","volume":"82","author":"Solomon","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cct.2025.108000_bb0060","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1002\/art.27457","article-title":"Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor \u03b1 therapy","volume":"62","author":"Cui","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.cct.2025.108000_bb0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1003394","article-title":"Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to Etanercept therapy in rheumatoid arthritis","volume":"9","author":"Cui","year":"2013","journal-title":"PLoS Genet."},{"key":"10.1016\/j.cct.2025.108000_bb0070","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/art.30130","article-title":"Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci","volume":"63","author":"Plant","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.cct.2025.108000_bb0075","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1136\/annrheumdis-2012-202405","article-title":"Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritis","volume":"72","author":"Umi\u010bevi\u010b Mirkov","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cct.2025.108000_bb0080","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2217\/pgs.13.60","article-title":"GWAS replication study confirms the association of PDE3A-SLCO1C1 with anti-TNF therapy response in rheumatoid arthritis","volume":"14","author":"Acosta-Colman","year":"2013","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.cct.2025.108000_bb0085","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/FPC.0b013e3283544043","article-title":"Investigation of single nucleotide polymorphisms and biological pathways associated with response to TNF\u03b1 inhibitors in patients with rheumatoid arthritis","volume":"22","author":"Krintel","year":"2012","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.cct.2025.108000_bb0090","first-page":"12","article-title":"Validation of GWAS-identified variants for anti-TNF drug response in rheumatoid arthritis: a meta-analysis of two large cohorts","author":"S\u00e1nchez-Maldonado","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cct.2025.108000_bb0095","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/tpj.2015.29","article-title":"Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis","volume":"16","author":"Ferreiro-Iglesias","year":"2016","journal-title":"Pharmacogenom. J."},{"key":"10.1016\/j.cct.2025.108000_bb0100","first-page":"24","article-title":"MTHFR c.665C>T and c.1298A>C polymorphisms in tailoring personalized anti-TNF-\u03b1 therapy for rheumatoid arthritis","author":"Ravaei","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cct.2025.108000_bb0105","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1136\/annrheumdis-2011-200337","article-title":"Fc\u03b3 receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab","volume":"71","author":"Ruyssen-Witrand","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cct.2025.108000_bb0110","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/s41397-019-0072-6","article-title":"A single nucleotide polymorphism of IL6-receptor is associated with response to tocilizumab in rheumatoid arthritis patients","volume":"19","author":"Luxembourger","year":"2019","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.cct.2025.108000_bb0115","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/tpj.2016.88","article-title":"Influence of IL6R gene polymorphisms in the effectiveness to treatment with tocilizumab in rheumatoid arthritis","volume":"18","author":"Maldonado-Montoro","year":"2018","journal-title":"Pharmacogenom. J."},{"key":"10.1016\/j.cct.2025.108000_bb0120","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/rheumatology\/keq155","article-title":"The National Data Bank for rheumatic diseases: a multi-registry rheumatic disease data bank","volume":"50","author":"Wolfe","year":"2011","journal-title":"Rheumatology"},{"key":"10.1016\/j.cct.2025.108000_bb0125","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1002\/acr.22984","article-title":"Development of the American College of Rheumatology\u2019s rheumatoid arthritis electronic clinical quality measures","volume":"68","author":"Yazdany","year":"2016","journal-title":"Arthrit. Care Res. (Hoboken)"},{"key":"10.1016\/j.cct.2025.108000_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2024.152421","article-title":"Reasons for multiple biologic and targeted synthetic DMARD switching and characteristics of treatment refractory rheumatoid arthritis","volume":"66","author":"McDermott","year":"2024","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.cct.2025.108000_bb0135","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/art.42767","article-title":"Poly-refractory rheumatoid arthritis: an uncommon subset of difficult to treat disease with distinct inflammatory and noninflammatory phenotypes","volume":"76","author":"David","year":"2023","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.cct.2025.108000_bb0140","doi-asserted-by":"crossref","DOI":"10.1093\/jamiaopen\/ooab110","article-title":"Generating real-world data from health records: design of a patient-centric study in multiple sclerosis using a commercial health records platform","volume":"5","author":"Hanson","year":"2022","journal-title":"JAMIA Open"},{"key":"10.1016\/j.cct.2025.108000_bb0145","doi-asserted-by":"crossref","first-page":"R796","DOI":"10.1186\/ar1740","article-title":"Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score","volume":"7","author":"Aletaha","year":"2005","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.cct.2025.108000_bb0150","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.rdc.2009.10.001","article-title":"The disease activity score and the EULAR response criteria","volume":"35","author":"Fransen","year":"2009","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"10.1016\/j.cct.2025.108000_bb0155","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1038\/s41588-022-01213-w","article-title":"Multi-ancestry genome-wide association analyses identify novel genetic mechanisms in rheumatoid arthritis","volume":"54","author":"Ishigaki","year":"2022","journal-title":"Nat. Genet."},{"key":"10.1016\/j.cct.2025.108000_bb0160","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41586-020-2222-z","article-title":"Notch signalling drives synovial fibroblast identity and arthritis pathology","volume":"582","author":"Wei","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.cct.2025.108000_bb0165","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41586-023-06708-y","article-title":"Deconstruction of rheumatoid arthritis synovium defines inflammatory subtypes","volume":"623","author":"Zhang","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.cct.2025.108000_bb0170","first-page":"7","article-title":"Decentralized clinical trials in the trial innovation network: value, strategies, and lessons learned","author":"Hanley","year":"2023","journal-title":"J. Clin. Transl. Sci."},{"key":"10.1016\/j.cct.2025.108000_bb0175","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.cct.2014.04.009","article-title":"Web-based trial to evaluate the efficacy and safety of tolterodine ER 4mg in participants with overactive bladder: REMOTE trial","volume":"38","author":"Orri","year":"2014","journal-title":"Contemp. Clin. Trials"},{"key":"10.1016\/j.cct.2025.108000_bb0180","doi-asserted-by":"crossref","first-page":"e390","DOI":"10.1016\/S2589-7500(23)00052-3","article-title":"Decentralised clinical trials: ethical opportunities and challenges","volume":"5","author":"Vayena","year":"2023","journal-title":"Lancet Digit Health"},{"key":"10.1016\/j.cct.2025.108000_bb0185","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41698-024-00613-x","article-title":"Polygenic risk scores for autoimmune related diseases are significantly different in cancer exceptional responders","volume":"8","author":"Chen","year":"2024","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.cct.2025.108000_bb0190","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s43441-022-00454-5","article-title":"Assessing the financial value of decentralized clinical trials","volume":"57","author":"DiMasi","year":"2023","journal-title":"Ther. Innov. Regul. Sci."},{"key":"10.1016\/j.cct.2025.108000_bb0195","first-page":"3","article-title":"Digitizing clinical trials","author":"Inan","year":"2020","journal-title":"NPJ Digit. Med."}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714425001946?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714425001946?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T07:33:00Z","timestamp":1779780780000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714425001946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":39,"alternative-id":["S1551714425001946"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2025.108000","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rationale and design of the rheumatoid arthritis non-responders to treatment (RANT) study: Use of a bioinformatics platform and \u201cdecentralized\u201d clinical recruitment design","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2025.108000","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108000"}}